MARKET

PTCT

PTCT

Ptc Therapeutics
NASDAQ
62.23
-0.06
-0.09%
Opening 10:09 09/25 EDT
OPEN
62.65
PREV CLOSE
62.28
HIGH
62.81
LOW
61.66
VOLUME
47.70K
TURNOVER
--
52 WEEK HIGH
90.87
52 WEEK LOW
57.74
MARKET CAP
5.19B
P/E (TTM)
-110.5633
1D
5D
1M
3M
1Y
5Y
1D
PTC Therapeutics (PTCT) Stock Looks Expensive As Its 175% Run Draws Focus
Simply Wall St · 8h ago
Analysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), NewAmsterdam Pharma Company (NAMS)
TipRanks · 3d ago
PTC Therapeutics Price Target Raised to $137.00/Share From $130.00 by Cantor Fitzgerald
Dow Jones · 3d ago
PTC Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 3d ago
Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $137
Benzinga · 3d ago
PTC Therapeutics Acquires Sangamo's Fabry Gene Therapy ST-920; Expects BLA Completion In Q4
NASDAQ · 3d ago
PTC Therapeutics Acquires Fabry Gene Therapy Candidate ST-920
TipRanks · 3d ago
*PTC Therapeutics: Completion of BLA Submission Expected in 4Q >PTCT
Dow Jones · 3d ago
More
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. It is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD), a rare life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its ST-920, or isaralgagene civaparvovec, is a one-time administered AAV gene therapy product candidate for the treatment of Fabry disease.

Webull offers PTC Therapeutics, Inc. stock information, including NASDAQ: PTCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCT stock methods without spending real money on the virtual paper trading platform.